ZA934603B - thiazolylvinylphenyl derivatives. - Google Patents

thiazolylvinylphenyl derivatives.

Info

Publication number
ZA934603B
ZA934603B ZA934603A ZA934603A ZA934603B ZA 934603 B ZA934603 B ZA 934603B ZA 934603 A ZA934603 A ZA 934603A ZA 934603 A ZA934603 A ZA 934603A ZA 934603 B ZA934603 B ZA 934603B
Authority
ZA
South Africa
Prior art keywords
thiazolylvinylphenyl
derivatives
thiazolylvinylphenyl derivatives
Prior art date
Application number
ZA934603A
Other languages
English (en)
Inventor
George William Holland
John Raymond Vermeulen
William Joseph Zally
Original Assignee
Hoffman La Roche A G F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman La Roche A G F filed Critical Hoffman La Roche A G F
Publication of ZA934603B publication Critical patent/ZA934603B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA934603A 1992-07-02 1993-06-25 thiazolylvinylphenyl derivatives. ZA934603B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/907,987 US5273986A (en) 1992-07-02 1992-07-02 Cycloalkylthiazoles

Publications (1)

Publication Number Publication Date
ZA934603B true ZA934603B (en) 1994-01-05

Family

ID=25424972

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA934603A ZA934603B (en) 1992-07-02 1993-06-25 thiazolylvinylphenyl derivatives.

Country Status (18)

Country Link
US (2) US5273986A (no)
EP (1) EP0577003A1 (no)
JP (1) JPH0680654A (no)
KR (1) KR940005602A (no)
CN (1) CN1087086A (no)
AU (1) AU667107B2 (no)
BR (1) BR9302737A (no)
CA (1) CA2099295A1 (no)
CZ (1) CZ133493A3 (no)
FI (1) FI933037A (no)
HU (1) HUT72747A (no)
IL (1) IL106141A0 (no)
MX (1) MX9303958A (no)
NO (1) NO932399L (no)
NZ (1) NZ247988A (no)
PL (1) PL299544A1 (no)
UY (1) UY23609A1 (no)
ZA (1) ZA934603B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
WO1996008479A1 (en) * 1994-09-13 1996-03-21 F. Hoffmann-La Roche Ag A process of making (e)-4-[3-[2-(4-cycloalkyl-2-thiazolyl)ethenyl]phenyl]amino-2,2-alkyldiyl-4-oxobutanoic acid
CA2202623A1 (en) * 1994-10-14 1996-04-25 Hitoshi Nagaoka Azole derivative
JPH11506425A (ja) * 1995-04-21 1999-06-08 第一製薬株式会社 エチニルチアゾール誘導体
SE9804212D0 (sv) * 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
CA2445697A1 (en) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
KR20070007104A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
EP1718624B1 (en) * 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006125958A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
NZ575512A (en) * 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
CN101595104A (zh) * 2006-12-21 2009-12-02 阿斯利康(瑞典)有限公司 作为glk活化剂的新的晶态化合物
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN102647984B (zh) 2009-10-02 2015-03-25 埃维克辛公司 抗炎症的2-羰基噻唑和2-羰基恶唑
US20150376161A1 (en) 2013-01-29 2015-12-31 Avexxin As Antiiflammatory and antitumor 2-oxothiazoles abd 2-oxothiophenes compounds
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20220324835A1 (en) * 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
MX2021013751A (es) 2019-05-17 2022-01-26 Nurix Therapeutics Inc Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos.
CA3152293A1 (en) 2019-09-24 2021-04-01 Arthur T. Sands Cbl inhibitors and compositions for use in adoptive cell therapy
KR20230167407A (ko) 2021-04-08 2023-12-08 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제제 화합물을 이용한 조합 요법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
DE3723913A1 (de) * 1987-07-18 1989-02-23 Shell Agrar Gmbh & Co Kg Neue phosphoniumsalze, ihre herstellung und verwendung
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
ES2052825T3 (es) * 1988-07-15 1994-07-16 Hoffmann La Roche Derivados de cicloalquiltiazol.
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH02169583A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
AU654140B2 (en) * 1990-07-31 1994-10-27 Lilly Industries Limited N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MX9303958A (es) 1994-04-29
JPH0680654A (ja) 1994-03-22
HU9301881D0 (en) 1993-09-28
CZ133493A3 (en) 1994-01-19
NO932399L (no) 1994-01-03
PL299544A1 (en) 1994-02-21
KR940005602A (ko) 1994-03-21
CN1087086A (zh) 1994-05-25
NO932399D0 (no) 1993-07-01
EP0577003A1 (en) 1994-01-05
IL106141A0 (en) 1993-10-20
US5273986A (en) 1993-12-28
UY23609A1 (es) 1993-12-21
FI933037A (fi) 1994-01-03
HUT72747A (en) 1996-05-28
CA2099295A1 (en) 1994-01-03
NZ247988A (en) 1995-11-27
FI933037A0 (fi) 1993-07-01
US5399702A (en) 1995-03-21
BR9302737A (pt) 1994-02-08
AU4156293A (en) 1994-01-06
AU667107B2 (en) 1996-03-07

Similar Documents

Publication Publication Date Title
ZA934603B (en) thiazolylvinylphenyl derivatives.
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
EP0597463A3 (en) Thermotherapiesonde.
EP0580285A3 (en) Auto-reclosers.
ZA919660B (en) Alpha-oxoacetamide derivatives.
PH30977A (en) Hiv-inhibiting benzene-acetamide derivatives.
EP0633771A4 (en) Compounds.
ZA941137B (en) Substitutet azolone derivatives.
GB9305306D0 (en) Pyrrolo-pyridazione derivatives
EP0572808A3 (de) Antiblockierregelsystem.
HU9301955D0 (en) Benzophenone-hydrazone derivatives
EP0668864A4 (en) SUBSTITUTED BIPHENYLMETHYLIMIDAZOPYRIDINES.
ZA931876B (en) 2-Oxoquinoline derivatives
OA09716A (en) Benzoxaiole derivatives.
EP0599191A3 (en) Engine speed control circuit.
ZA932639B (en) Propenoyl-imidazole derivatives
EP0592354A3 (de) Vakuum-Zentrifuge.
EP0663819A4 (en) IBUPROFEN-COFFEINE COMBINATIONS.
GB2270913B (en) Chlordifluoromethoxyphenyl derivatives
GB2271564B (en) Thioalkylthio carbacephalosporin derivatives
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
EP0624089A4 (en) Methods.
ZA935828B (en) New insobutyl-substituted methanesulphonyl-quinolyl-methoxyphenyl-cycloalkylacetamides.
ZA935478B (en) Lactam derivatives.
EP0565961A3 (en) Ethyl-triazolyl derivatives